TrialGynecologic oncology2021

Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer.

Payal D Shah et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.